当前位置:
X-MOL 学术
›
Curr. Pain Headache Rep.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Evaluation of Cost-Utility of Thoracic Interlaminar Epidural Injections.
Current Pain and Headache Reports ( IF 3.7 ) Pub Date : 2020-01-30 , DOI: 10.1007/s11916-020-0838-1 Laxmaiah Manchikanti 1, 2, 3, 4 , Vidyasagar Pampati 4 , Satya P Sanapati 5 , Mahendra R Sanapati 6 , Alan D Kaye 7 , Joshua A Hirsch 8
中文翻译:
胸膜间硬膜外注射的成本-效用评估。
更新日期:2020-01-30
Current Pain and Headache Reports ( IF 3.7 ) Pub Date : 2020-01-30 , DOI: 10.1007/s11916-020-0838-1 Laxmaiah Manchikanti 1, 2, 3, 4 , Vidyasagar Pampati 4 , Satya P Sanapati 5 , Mahendra R Sanapati 6 , Alan D Kaye 7 , Joshua A Hirsch 8
Affiliation
Purpose of Review
Chronic thoracic pain, even though not as prevalent as low back and neck pain, appears in approximately 30% of the general population. The severity of thoracic pain and degree of disability seems to be similar to other painful conditions. Despite this severity, interventions in managing chronic thoracic pain are less frequent, and there is a paucity of literature regarding epidural injections and facet joint interventions.Recent Findings
As with lumbar and cervical spine, a multitude of interventions are offered in managing chronic thoracic pain, including interventional techniques with epidural injections and facet joint interventions. A single randomized controlled trial (RCT) has been published with a 2-year follow-up of clinical effectiveness of the results. However, there have not been any cost-utility analysis studies pertaining to either epidural injections or facet joint interventions in thoracic pain. Based on the results of the RCT, a cost-utility analysis of thoracic interlaminar epidural injections was undertaken.Summary
Evaluation of the cost-utility analysis of thoracic interlaminar epidural injections with or without steroids in managing thoracic disc herniation, thoracic spinal stenosis, and thoracic discogenic or axial pain was assessed in 110 patients with a 2-year follow-up. Direct payment data from 2018 was utilized for procedural costs and indirect costs. Costs, including drug costs, were determined by multiplication of direct procedural payment data by a factor of 1.67 or addition of 40% of cost to accommodate for indirect payments and arrive at overall costs. Cost-utility analysis showed direct procedural cost of USD $1943.19, whereas total estimated costs year per QALY were USD $3245.12.中文翻译:
胸膜间硬膜外注射的成本-效用评估。